Discussion OW GLP-1RAs (i.e., dulaglutide, OW exenatide, and OW semaglutide) were proven to give benefits on glucose control, body weight reduction, cardiovascular risk factors, and outcomes in subjects with T2D as shown by previous RCTs and CVOT data (16)
Diabetes Obes Metab 19(6):901905
While this may be convenient, it is essential to consider that the potential risks are much higher in such a scenario
Novo Nordisk and Pfizer and AstraZeneca and Eli Lilly and Roche and a handful of Chinese developers are all racing to figure out which oral approach actually works at scale
(2) Phenotypic conversion: a
[DOI] [PubMed] [Google Scholar] 47.Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, et al